Citigroup
CADL icon

Citigroup’s Candel Therapeutics CADL Stock Holding History

Citigroup’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$881K Buy
85,510
+64,128
+300% +$484K ﹤0.01% 3536
2026
Q1 		$105K Buy
21,382
+18,708
+700% +$102K ﹤0.01% 4268
2025
Q4 		$15.1K Buy
2,674
+963
+56% +$5.18K ﹤0.01% 4942
2025
Q3 		$8.73K Sell
1,711
-12,224
-88% -$70.6K ﹤0.01% 5065
2025
Q2 		$70.5K Sell
13,935
-6,303
-31% -$32.4K ﹤0.01% 4586
2025
Q1 		$114K Buy
20,238
+1,635
+9% +$13.4K ﹤0.01% 4521
2024
Q4 		$161K Buy
18,603
+4,113
+28% +$24.3K ﹤0.01% 4543
2024
Q3 		$100K Buy
14,490
+9,892
+215% +$61.5K ﹤0.01% 4760
2024
Q2 		$28.5K Buy
+4,598
New +$34.5K ﹤0.01% 4886
2023
Q3 		– Sell
-118,612
Closed -$149K – 5679
2023
Q2 		$149K Buy
+118,612
New +$175K ﹤0.01% 4036
2023
Q1 		– Sell
-352
Closed -$630 – 5522
2022
Q4 		$630 Buy
352
+17
+5% +$34 ﹤0.01% 5472
2022
Q3 		$1K Sell
335
-95
-22% -$322 ﹤0.01% 5608
2022
Q2 		$1K Sell
430
-180
-30% -$721 ﹤0.01% 5986
2022
Q1 		$3K Sell
610
-256
-30% -$1.27K ﹤0.01% 5945
2021
Q4 		$7K Buy
+866
New +$8.41K ﹤0.01% 5618

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup's CADL Position: Q2 2026 in Review

Citigroup increased its Candel Therapeutics (CADL) stake by 300% in Q2 2026, buying an estimated $484K and bringing the position to 85,510 shares worth $881K. The position accounts for ﹤0.01% of the portfolio, ranked #3536.

Citigroup first reported a position in CADL in Q4 2021 and has held it in 15 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Citigroup held 85,510 shares of Candel Therapeutics worth $881K as of Q2 2026.
  • Citigroup bought 64,128 Candel Therapeutics shares in Q2 2026, an estimated $484K.
  • Candel Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3536 holding.
  • Citigroup first reported a position in Candel Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.